Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe)

National Institutes of Health

Description

The National Cancer Institute (NCI) is inviting applications for R21 grants aimed at high-risk, high-reward research in cancer immunology. The goal is to explore new ideas or technologies that could enhance our understanding of immune responses, tumor-immune interactions, and immune networks related to cancer. These projects should be innovative and different from typical R01 projects, with the potential to make significant breakthroughs in cancer immunology and treatment.

The National Cancer Institute (NCI) is encouraging R21 applications for innovative high-risk/high-reward research projects in cancer immunology. The focus is on novel hypotheses or technologies to advance understanding of cancer immunology, including immune responses, tumor-immune ecosystems, an…

Source

Grant ID

NOT-CA-24-016

Agency

National Institutes of Health

Subcategory/Subagency

National Cancer Institute

Key Dates

Opportunity Released

December 5, 2023

Eligibility

The following categories of applicants are invited to apply:

  • Higher Education Institutions — Public/State-controlled Institutions of Higher Education
  • Higher Education Institutions — Private Institutions of Higher Education
  • Nonprofit Organizations with 501(c)(3) status (other than Institutions of Higher Education)
  • Nonprofit Organizations without 501(c)(3) status (other than Institutions of Higher Education)
  • For-Profit Organizations (other than Small Businesses)
  • Small Businesses
  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American Tribal Governments (Federally recognized)
  • Native American Tribal Governments (Other than Federally recognized)
  • Native American Tribal Organizations (other than Federally recognized Tribal Governments)
  • U.S. Territories or Possessions
  • Eligible Agencies of the Federal Government
  • Regional Organizations
  • Faith-based Organizations
  • Non-domestic (non-U.S.) components of U.S. Organizations — as allowed by the parent NOFOs
  • Community-based Organizations
  • Foreign/Non-domestic Entities (Foreign Institutions) — as allowed by the parent NOFOs (PA-20-195, PA-20-196)
  • Foreign components of U.S. projects — as allowed by the parent NOFOs
Additional Eligibility Information
This is a Notice of Special Interest (NOSI) from NCI (NOT-CA-24-016). Applications must be submitted under one of the specified parent R21 NOFOs and follow all SF424 (R&R) and NOFO instructions. Key conditions: 1) Submit under PA-20-195 (NIH Parent R21, Clinical Trial Not Allowed) or PA-20-196 (NIH Parent R21, Basic Experimental Studies with Humans Required). 2) For funding consideration under this NOSI, applicants must include “NOT-CA-24-016” in box 4B (Agency Routing Identifier) of the SF424 …
Links
Similar opportunities

Save this grant and explore more opportunities

Share Grant

Share this grant opportunity with others.
Anyone with this link can view the grant details.